NCT06240351View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)

PHASE4RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 22, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2027

Conditions
Frontal Fibrosing Alopecia
Interventions
DRUG

Baricitinib 4 MG Oral Tablet

Baricitinib is a Janus kinase (JAK) inhibitor

Trial Locations (1)

35233

RECRUITING

University of Alabama at Birmingham, Birmingham

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

University of Alabama at Birmingham

OTHER